KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 6

Paradigm shifts in non-small cell lung cancer imaging: a bibliometric and thematic analysis of the top 100 highly cited articles (2016–2026)

Abdullah Enes Ataş(NECMETTİN ERBAKAN ÜNİVERSİTESİ, MERAM TIP FAKÜLTESİ)0000-0001-6623-3024
Abdurrahman Koç(Meram Devlet Hastanesi)0000-0002-4462-0944
Hasan Eryeşil(Tatvan Devlet Hastanesi)0000-0002-9353-4647
Sayfa
—
Yayın Tarihi
2026-10-25
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Overcoming standardization bottlenecks and developing multimodal systems are crucial for integrating these robust models into clinical workflows.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: To conduct a bibliometric and thematic analysis of the 100 most-cited articles published over the last decade concerning the intersection of non-small cell lung cancer (NSCLC) and radiology, highlighting paradigm shifts and current research trends.
📊
Temel Bulgular & Veri:Methods: The Web of Science Core Collection was queried for literature on NSCLC and radiology/imaging published between 2016 and 2026.
💡
Sonuç & Katkı:Overcoming standardization bottlenecks and developing multimodal systems are crucial for integrating these robust models into clinical workflows.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2016 Verileri
⚙️Değişkenler:Carcinoma · non-small-cell lung · radiomics

Abstract

Aims: To conduct a bibliometric and thematic analysis of the 100 most-cited articles published over the last decade concerning the intersection of non-small cell lung cancer (NSCLC) and radiology, highlighting paradigm shifts and current research trends. Methods: The Web of Science Core Collection was queried for literature on NSCLC and radiology/imaging published between 2016 and 2026. The top 100 most-cited original articles and reviews were extracted. Data were categorized thematically and mapped bibliometrically using VOSviewer to analyze keyword co-occurrence and chronological evolution. Results: The thematic analysis revealed that “Artificial Intelligence (AI) & Deep Learning” (25 articles, 9711 citations) and “treatment response & Prognosis” (26 articles, 6271 citations) dominated the high-impact literature. Timeline mapping demonstrated a notable shift from traditional anatomical staging toward predictive radiomics, deep learning models, and immunotherapy evaluation. The Lancet Oncology and Harvard University emerged as the leading journal and institution, respectively. Despite high citation rates, a lack of methodological standardization in image processing remains a significant barrier to clinical translation. Conclusion: NSCLC radiology has evolved from a qualitative morphological evaluation into a quantitative, AI-driven discipline capable of predicting genetic mutations and treatment outcomes. Overcoming standardization bottlenecks and developing multimodal systems are crucial for integrating these robust models into clinical workflows.

🔖

Bu Makaleye Atıf Yap

Ataş, A. E., Koç, A., Eryeşil, H. (2026). Paradigm shifts in non-small cell lung cancer imaging: a bibliometric and thematic analysis of the top 100 highly cited articles (2016–2026). Journal of Health Sciences and Medicine, Volume: 9 Issue: 6. https://ajindex.com/articles/1668024

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (55)

  1. Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71. doi:10.1038/s41572-024-00551-9
  2. Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(1):63-70. doi:10.1080/14737140.2018.1409624
  3. Zhou M, Leung A, Echegaray S, et al. Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications. Radiology. 2018; 286(1):307-315. doi:10.1148/radiol.2017161845
  4. Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer: an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422): 171-182. doi:10.1016/S0140-6736(23)01857-3
  5. Rallis KS, Makker S, Ghose A, Sideris M. Assessing radiological response to immunotherapy in lung cancer: an evolving arena. Cancer Diagn Progn. 2024;4(1):1-8. doi:10.21873/cdp.10278
  6. Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi:10.3389/fimmu.2018.01474
  7. Serindere M. Bibliometric analysis of the 50 most cited articles on Artificial Intelligence for lung cancer imaging. J Health Sci Med. 2023; 6(3):686-692. doi:10.32322/jhsm.1294551
  8. van Velden FHP, Kramer GM, Frings V, et al. Repeatability of radiomic features in non-small-cell lung cancer (18F) FDG-PET/CT studies: impact of reconstruction and delineation. Mol Imaging Biol. 2016;18(5): 788-795. doi:10.1007/s11307-016-0940-2
  9. Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018;24(10):1559-1567. doi:10.1038/s41591-018-0177-5
  10. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-1640. doi:10.1016/j.mayocp.2019.01.013
  11. Lu MY, Williamson DFK, Chen TY, Chen RJ, Barbieri M, Mahmood F. Data-efficient and weakly supervised computational pathology on whole-slide images. Nat Biomed Eng. 2021;5(6):555-570. doi:10.1038/s41551-020-00682-w
  12. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617. doi:10.1016/S0140-6736(21)02333-3
  13. Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/S1470-2045(16)30532-0
  14. Hensley CT, Faubert B, Yuan Q, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164(4):681-694. doi:10.1016/j.cell.2015.12.034
  15. Traverso A, Wee L, Dekker A, Gillies RJ. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys. 2018;102(4):1143-1158. doi:10.1016/j.ijrobp.2018.05.053
  16. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511-1521. doi:10.1093/neuonc/nox077
  17. Huang YQ, Liu ZY, He L, et al. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology. 2016;281(3):947-957. doi:10.1148/radiol.2016152234
  18. Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070. doi:10.1098/rsob.170070
  19. Chen PX, Liu YH, Wen YK, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937-970. doi:10.1002/cac2.12359
  20. Yang JCH, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288-1296. doi:10.1200/JCO.2016.70.3223
  21. Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7): 914-922. doi:10.1016/S1470-2045(20)30314-4
  22. Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655-663. doi:10.1016/S1470-2045(20)30111-X
  23. Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853-1860. doi:10.1093/annonc/mdy218
  24. Hosny A, Parmar C, Coroller TP, et al. Deep learning for lung cancer prognostication: a retrospective multi-cohort radiomics study. PLoS Med. 2018;15(11):e1002711. doi:10.1371/journal.pmed.1002711
  25. Xu YW, Hosny A, Zeleznik R, et al. Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res. 2019; 25(11):3266-3275. doi:10.1158/1078-0432.CCR-18-2495
  26. Beig N, Khorrami M, Alilou M, et al. Perinodular and intranodular radiomic features on lung CT images distinguish adenocarcinomas from granulomas. Radiology. 2019;290(3):783-792. doi:10.1148/radiol.2018180910
  27. Jiang J, Hu YC, Liu CJ, et al. Multiple resolution residually connected feature streams for automatic lung tumor segmentation from CT images. IEEE Trans Med Imaging. 2019;38(1):134-144. doi:10.1109/TMI.2018.2857800
  28. Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. 2016;26(1):32-42. doi:10.1007/s00330-015-3814-0
  29. Zhang JY, Zhao XM, Zhao Y, et al. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1137-1146. doi:10.1007/s00259-019-04592-1
  30. Kim DW, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452-463. doi:10.1016/S1470-2045(15)00614-2
  31. Aerts H, Grossmann P, Tan YQ, et al. Defining a radiomic response phenotype: a pilot study using targeted therapy in NSCLC. Sci Rep. 2016; 6:33860. doi:10.1038/srep33860
  32. Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38-47. doi:10.1016/j.ejca.2017.10.017
  33. Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30(6):998-1004. doi:10.1093/annonc/mdz108
  34. Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. Cancer Immunol Res. 2020;8(1):108-119. doi:10.1158/2326-6066.CIR-19-0476
  35. Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest. 2021;160(2):731-742. doi:10.1016/j.chest.2021.02.032
  36. Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150-156. doi:10.1016/j.lungcan.2018.09.015
  37. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43-50. doi:10.1136/annrheumdis-2016-209595
  38. Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med. 2023;11(6):540-549. doi:10.1016/S2213-2600(23)00041-3
  39. Dai CY, Shen JF, Ren YJ, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤1 cm or >1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34(26):3175-3182. doi:10.1200/JCO.2015.64.6729
  40. Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127(1):1-5. doi:10.1016/j.radonc.2018.02.023
  41. Huynh E, Coroller TP, Narayan V, et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. Radiother Oncol. 2016;120(2):258-266. doi:10.1016/j.radonc.2016.05.024
  42. Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(5):651-665. doi:10.1016/j.jtho.2016.01.025
  43. Zhang YC, Oikonomou A, Wong A, Haider MA, Khalvati F. Radiomics-based prognosis analysis for non-small cell lung cancer. Sci Rep. 2017;7: 46349. doi:10.1038/srep46349
  44. Fornacon-Wood I, Mistry H, Ackermann CJ, et al. Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. Eur Radiol. 2020;30(11):6241-6250. doi:10.1007/s00330-020-06957-9
  45. Shafiq-ul-Hassan M, Latifi K, Zhang G, Ullah G, Gillies R, Moros E. Voxel size and gray level normalization of CT radiomic features in lung cancer. Sci Rep. 2018;8(1):10545. doi:10.1038/s41598-018-28895-9
  46. Zwanenburg A, Leger S, Agolli L, et al. Assessing robustness of radiomic features by image perturbation. Sci Rep. 2019;9(1):614. doi:10.1038/s41598-018-36938-4
  47. Pavic M, Bogowicz M, Würms X, et al. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncol. 2018;57(8):1070-1074. doi:10.1080/0284186X.2018.1445283
  48. Vanguri RS, Luo J, Aukerman AT, et al. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022;3(10):1151-1164. doi:10.1038/s43018-022-00416-8
  49. Simon BD, Ozyoruk KB, Gelikman DG, Harmon SA, Türkbey B. The future of multimodal Artificial Intelligence models for integrating imaging and clinical metadata: a narrative review. Diagn Interv Radiol. 2025;31(4):303-312. doi:10.4274/dir.2024.242631
  50. Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396-412.e5. doi:10.1016/j.ccell.2023.12.021
  51. Prelaj A, Miskovic V, Zanitti M, et al. Artificial Intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35(1):29-65. doi:10.1016/j.annonc.2023.10.125
  52. Fave X, Zhang LF, Yang JZ, et al. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep. 2017;7:588. doi:10.1038/s41598-017-00665-z
  53. Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021; 12(1):5060. doi:10.1038/s41467-021-24994-w
  54. Nilsson RJA, Karachaliou N, Berenguer J, et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget. 2016;7(1):1066-1075. doi:10.18632/oncotarget.6279
  55. Goldberg SB, Narayan A, Kole AJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872-1880. doi:10.1158/1078-0432.CCR-17-1341